keyword
MENU ▼
Read by QxMD icon Read
search

Letrozole

keyword
https://www.readbyqxmd.com/read/28238593/her2-enriched-subtype-as-a-predictor-of-pathological-complete-response-following-trastuzumab-and-lapatinib-without-chemotherapy-in-early-stage-her2-positive-breast-cancer-pamela-an-open-label-single-group-multicentre-phase-2-trial
#1
Antonio Llombart-Cussac, Javier Cortés, Laia Paré, Patricia Galván, Begoña Bermejo, Noelia Martínez, Maria Vidal, Sònia Pernas, Rafael López, Montserrat Muñoz, Paolo Nuciforo, Serafín Morales, Mafalda Oliveira, Lorena de la Peña, Alexandra Peláez, Aleix Prat
BACKGROUND: HER2-positive breast cancer consists of four intrinsic molecular subtypes-luminal A, luminal B, HER2-enriched, and basal-like-and a normal-like subtype, with the HER2-enriched subtype having the highest activation of the EGFR-HER2 pathway. We aimed to test the hypothesis that patients with the HER2-enriched subtype benefit the most from dual HER2 blockade. METHODS: PAMELA is an open-label, single-group, phase 2 trial done in 19 hospitals in Spain. We recruited female patients aged at least 18 years with previously untreated, centrally confirmed HER2-positive, stage I-IIIA invasive breast cancer regardless of hormone receptor status...
February 23, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28236310/clomiphene-and-letrozole-for-reducing-fsh-consumption-during-ovarian-stimulation-systematic-review-and-meta-analysis
#2
REVIEW
Tatiana N B Marcal, Mariane N Nadai, Carolina O Nastri, Wellington P Martins
OBJECTIVE: to assess the available evidence comparing effectiveness of ovarian stimulation (OS) using clomiphene (CC) and/or letrozole (LTZ) for reducing FSH consumption compared with standard OS. METHODS: We performed a systematic review and meta-analyses of randomized controlled trials (RCTs) that compared the reproductive outcomes following in vitro fertilization. We searched eleven electronic databases and hand-searched the reference list of included studies and related reviews...
February 25, 2017: Ultrasound in Obstetrics & Gynecology
https://www.readbyqxmd.com/read/28207416/are-aromatase-inhibitors-in-boys-with-predicted-short-stature-and-or-rapidly-advancing-bone-age-effective-and-safe
#3
Jessica A Ferris, Mitchell E Geffner
BACKGROUND: The aim of this study was to assess aromatase inhibitor (AI) efficacy in increasing predicted adult height (PAH) and to describe clinical and biochemical safety profiles of AI-treated boys. METHODS: A retrospective chart review was conducted at an academic children's hospital endocrinology clinic. Twenty-one boys with predicted short stature and/or rapidly advancing bone age, divided as Tanner stage (TS) I-III Group 1 (G1, n=9) and TS IV-V Group 2 (G2, n=12), were treated with AIs, either letrozole or anastrozole (mean duration, G1: 2...
February 16, 2017: Journal of Pediatric Endocrinology & Metabolism: JPEM
https://www.readbyqxmd.com/read/28203301/progress-with-palbociclib-in-breast-cancer-latest-evidence-and-clinical-considerations
#4
REVIEW
Andrea Rocca, Alessio Schirone, Roberta Maltoni, Sara Bravaccini, Lorenzo Cecconetto, Alberto Farolfi, Giuseppe Bronte, Daniele Andreis
Deregulation of the cell cycle is a hallmark of cancer, and research on cell cycle control has allowed identification of potential targets for anticancer treatment. Palbociclib is a selective inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6), which are involved, with their coregulatory partners cyclin D, in the G1-S transition. Inhibition of this step halts cell cycle progression in cells in which the involved pathway, including the retinoblastoma protein (Rb) and the E2F family of transcription factors, is functioning, although having been deregulated...
February 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/28202255/alleviation-of-ischaemia-reperfusion-injury-by-endogenous-estrogen-involves-maintaining-bcl-2-expression-via-the-er%C3%AE-signalling-pathway
#5
Zeng-Li Zhang, Pei Qin, Yuhong Liu, Li-Xia Zhang, Hang Guo, You-Liang Deng, Yizhao-Liu, Yu-Shu Hou, Li-Yang Wang, Yi Miao, Yu-Long Ma, Wu-Gang Hou
The neuroprotective effects of estrogen against cerebral ischaemia have been confirmed by multiple basic and clinical studies. However, most of these studies used exogenous estrogen administered via different injection methods, and the neuroprotective effects of endogenous estrogen produced by ovaries during different phases of estrous cycle and the underlying mechanisms involved have rarely been explored. In this study, we first identified the stage of estrous cycle via vaginal smears and then measured serum estradiol levels at each phase via radioimmunoassay...
February 12, 2017: Brain Research
https://www.readbyqxmd.com/read/28195993/subcutaneous-testosterone-letrozole-therapy-before-and-concurrent-with-neoadjuvant-breast-chemotherapy-clinical-response-and-therapeutic-implications
#6
Rebecca L Glaser, Anne E York, Constantine Dimitrakakis
OBJECTIVE: Hormone receptor-positive breast cancers respond favorably to subcutaneous testosterone combined with an aromatase inhibitor. However, the effect of testosterone combined with an aromatase inhibitor on tumor response to chemotherapy was unknown. This study investigated the effect of testosterone-letrozole implants on breast cancer tumor response before and during neoadjuvant chemotherapy. METHODS: A 51-year-old woman on testosterone replacement therapy was diagnosed with hormone receptor-positive invasive breast cancer...
February 13, 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28195257/pathological-complete-response-in-a-patient-affected-by-multiple-synchronous-breast-and-lung-primary-malignancies-a-case-report-and-review-of-the-literature
#7
A Nottegar, C Luchini, S Cingarlini, S Beccari, E Grego, E Gilioli, E Manfrin, F Bonetti
A pathological complete response in a patient affected by multiple synchronous, breast and lung primary malignancies is reported. A 63-year-old woman presented with an invasive ductal carcinoma of the breast and a lung adenocarcinoma. After multidisciplinary discussion, the patient underwent pulmonary left lower lobectomy followed by radio-chemotherapy with cisplatin and vinorelbine and started hormone therapy with letrozole. Ten months later, a left mastectomy with axillary lymph nodes dissection was performed...
December 2016: Pathologica
https://www.readbyqxmd.com/read/28187961/a-retrospective-analysis-of-ovarian-stimulation-with-letrozole-in-women-undergoing-artificial-insemination-by-donor
#8
X J Sun, L Jiang, L C Ji, R Nie, H Chen, L Jin, G J Zhu, K Qian
The aim of this retrospective study was to determine the clinical pregnancy rate in women undergoing letrozole ovarian stimulation and artificial insemination by donor (AID). Between 2012 and 2015, 130 natural cycles, 939 letrozole cycles and 130 letrozole plus gonadotrophin cycles were conducted. Letrozole cycles were divided into three groups according to LH concentration on the day of HCG administration (LH <10 mIU/ml and follicle size ≥18 cm; LH ≤10 to <20 mIU/ml; and LH ≥20 mIU/ml). Pregnancy rates were 17...
January 25, 2017: Reproductive Biomedicine Online
https://www.readbyqxmd.com/read/28187771/the-effect-of-estradiol-on-granulosa-cell-responses-to-fsh-in-women-with-polycystic-ovary-syndrome
#9
Michael V Homer, Marcus A Rosencrantz, Rana F Shayya, R Jeffrey Chang
BACKGROUND: The influence of estradiol (E2) on granulosa cell (GC) function has not been tested clinically in women with polycystic ovary syndrome (PCOS). The objective of this study is to determine if E2 influences GC responses to FSH in women with PCOS. METHODS: This is a two phase, single cohort study conducted over a 2-year period at a single academic center. Nine women with PCOS according to NIH criteria. In Phase 1, FSH stimulation of GC responses as measured by E2 and Inhibin B (Inh B) were assessed before and at 5 and 6 weeks after GnRH agonist administration...
February 10, 2017: Reproductive Biology and Endocrinology: RB&E
https://www.readbyqxmd.com/read/28185930/fabrication-of-letrozole-formulation-using-chitosan-nanoparticles-through-ionic-gelation-method
#10
Thandapani Gomathi, P N Sudha, J Annie Kamala Florence, Jayachandran Venkatesan, Sukumaran Anil
In this study, the anticancer drug letrozole (LTZ) was formulated using chitosan nanoparticles (CS-NPs) with the crosslinking agent sodium tripolyphosphate (TPP). The nano-formulation was optimized by varying the concentration of drug. The prepared particles were characterized using FTIR, TGA, XRD, SEM, TEM and DLS. From the FTIR results, the appearance of a new peak for CH, CC and CN confirms the formation of LTZ loaded chitosan nanoparticles. TEM images shows that the average particle size was in the range of 60-80nm and 20-40mm air dried and freeze dried samples respectively...
February 7, 2017: International Journal of Biological Macromolecules
https://www.readbyqxmd.com/read/28178667/anti-gd2-ch14-18-cho-coated-nanoparticles-mediate-glioblastoma-gbm-specific-delivery-of-the-aromatase-inhibitor-letrozole-reducing-proliferation-migration-and-chemoresistance-in-patient-derived-gbm-tumor-cells
#11
Amanda Tivnan, Tatjana Heilinger, Joanne Ramsey, Gemma O'Connor, Jenny Pokorny, Jann Sarkaria, Brett Stringer, Bryan Day, Andrew Boyd, Ella Kim, Holger Lode, Sally-Ann Cryan, Jochen Prehn
Aromatase is a critical enzyme in the irreversible conversion of androgens to oestrogens, with inhibition used clinically in hormone-dependent malignancies. We tested the hypothesis that targeted aromatase inhibition in an aggressive brain cancer called glioblastoma (GBM) may represent a new treatment strategy. In this study, aromatase inhibition was achieved using third generation inhibitor, Letrozole, encapsulated within the core of biodegradable poly lactic-co-glycolic acid (PLGA) nanoparticles (NPs). PLGA-NPs were conjugated to human/mouse chimeric anti-GD2 antibody ch14...
February 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/28177754/comparison-of-the-effects-of-nobiletin-and-letrozole-on-the-activity-and-expression-of-aromatase-in-mcf-7-breast-cancer-cell-line
#12
Seyedeh Tayebeh Rahideh, Mohammad Keramatipour, Mitra Nourbakhsh, Fariba Koohdani, Mostafa Hoseini, Saeed Talebi, Farzad Shidfar
Nobiletin (NOB) is one of the polymethoxyflavones mainly found in citrus fruits. Aromatase or cytochrome P450 (CYP19) enzyme catalyzes the last and rate-limiting step in estrogen biosynthesis. This study was carried out to investigate the effect of NOB on the activity and expression of aromatase and compare this property with letrozole (LET) as aromatase inhibitor in MCF-7 breast cancer cell line. The cell viability was assessed by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) assays...
February 1, 2017: Biochemistry and Cell Biology, Biochimie et Biologie Cellulaire
https://www.readbyqxmd.com/read/28173995/gnrh-antagonist-and-letrozole-co-treatment-in-diminished-ovarian-reserve-patients-a-proof-of-concept-study
#13
Safak Olgan, Peter Humaidan
The current study aimed to investigate the effects of luteal gonadotropin-releasing hormone (GnRH) antagonist pretreatment on the outcomes of diminished ovarian reserve (DOR) patients who were treated using a FSH/letrozole/GnRH antagonist (FLA) protocol. Thus, patients who had luteal GnRH antagonist pretreatment (AFLA) prior to stimulation were compared to patients who had the FLA protocol, only. An electronic database was used to identify patients and stimulation characteristics. Women who had a total antral follicle count (AFC) of <7 were included in the analysis...
February 4, 2017: Reproductive Biology
https://www.readbyqxmd.com/read/28163101/identification-of-mirnas-as-biomarkers-for-acquired-endocrine-resistance-in-breast-cancer
#14
Penn Muluhngwi, Carolyn M Klinge
Therapies targeting estrogen receptor α (ERα) including tamoxifen, a selective estrogen receptor modulator (SERM) and aromatase inhibitors (AI), e.g., letrozole, have proven successful in reducing the death rate for breast cancer patients whose initial tumors express ERα. However, about 40% of patients develop acquired resistance to these endocrine treatments. There is a critical need to develop sensitive circulating biomarkers that accurately identify signaling pathways altered in breast cancer patients resistant to endocrine therapies...
February 2, 2017: Molecular and Cellular Endocrinology
https://www.readbyqxmd.com/read/28163005/letrozole-not-superior-to-anastrozole-for-early-breast-cancer
#15
Vicki Brower
No abstract text is available yet for this article.
February 2, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28152498/extended-adjuvant-endocrine-therapy-a-standard-to-all-or-some
#16
REVIEW
Domen Ribnikar, Berta Sousa, Tanja Cufer, Fatima Cardoso
Patients with estrogen receptor-positive (ER +) early breast cancer (EBC) are at a continuous risk for distant relapse despite 5 years of standard endocrine therapy, even after 10-15 years after primary diagnosis. Hence, large randomized clinical trials were conducted to evaluate the role of extended endocrine treatment (ET) with the primary goal to prevent or at least delay distant relapse. Two very large trials of extended tamoxifen (TAM), the ATLAS and the aTTom trial, proved the efficacy of prolonged TAM particularly important after 10 years due to the carry-over effect of the five initial years...
January 30, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28143834/treatment-strategies-for-women-with-who-group-ii-anovulation-systematic-review-and-network-meta-analysis
#17
Rui Wang, Bobae V Kim, Madelon van Wely, Neil P Johnson, Michael F Costello, Hanwang Zhang, Ernest Hung Yu Ng, Richard S Legro, Siladitya Bhattacharya, Robert J Norman, Ben Willem J Mol
OBJECTIVE:  To compare the effectiveness of alternative first line treatment options for women with WHO group II anovulation wishing to conceive. DESIGN:  Systematic review and network meta-analysis. DATA SOURCES:  Cochrane Central Register of Controlled Trials, Medline, and Embase, up to 11 April 2016. STUDY SELECTION:  Randomised controlled trials comparing eight ovulation induction treatments in women with WHO group II anovulation: clomiphene, letrozole, metformin, clomiphene and metformin combined, tamoxifen, gonadotropins, laparoscopic ovarian drilling, and placebo or no treatment...
January 31, 2017: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/28133341/-two-cases-of-lung-metastasis-from-breast-cancer-successfully-treated-with-endocrine-therapy
#18
Kumi Hasegawa, Yasuhiro Higashi, Ayako Kamiya, Yasushi Takatsuno, Ito Kondo, Jun Kaneko, Takeshi Endo, Shizuaki Maejima
We report 2 cases of lung metastasis from breast cancer that were successfully treated with endocrine therapy.Case 1 is a 69-year-old woman with cirrhosis of the liver caused by hepatitis C.She underwent surgery for left breast cancer at the age of 58, and surgery for right breast cancer at the age of 65.Four years later, she was diagnosed with lung metastasis of breast cancer.She received letrozole and the treatment was effective.Because the severity of the pleural effusion increased 3 years later, fulvestrant was subsequently administered...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28133221/-a-case-of-interstitial-pneumonitis-induced-by-lapatinib-plus-letrozole
#19
Daigo Yamamoto, Chizuko Yamamoto, Mitsuo Yamamoto
Lapatinib is an orally bioavailable dual inhibitor of the intracellular domain of both the HER2 protein and the epidermal growth factor receptor. This dual inhibitor can effectively prevent the downstream signal transduction initiated by a tyrosine kinase, thereby reducing the proliferation rate of tumor cells. Lapatinib was demonstrated to be beneficial in patients with HER2-positive locally advanced and metastatic breast cancer. We present here a case of interstitial pneumonitis that occurred after lapatinib treatment...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28133215/-long-term-survival-of-a-patient-with-stage-iv-breast-cancer-and-an-intrathoracic-space-occupying-metastatic-lesion
#20
Toshimori Koh, Tomohito Sakai, Shunji Kato, Shoji Hirajima, Minoru Nishio, Koji Soga, Atsushi Oguro, Noboru Nakagawa
A 50-year old woman noticed left axillary lymph node swelling and presented at our hospital. CNB showed adenocarcinoma( pap-tub, ER+, PgR+, HER2 3+). CT revealed a right lung metastatic nodule and swollen lymph nodes above the left collarbone and left axilla. However, no breast tumor was found at that time. We diagnosed occult breast cancer, TxN3bM1 (lung), Stage IV . FEC(100), paclitaxel, letrozole, anastrozole, exemestane plus trastuzumab, tegafur/uracil plus trastuzumab, and lapatinib plus capecitabine were sequentially administered...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
keyword
keyword
10315
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"